This article has been updated with a statement from Guardant Health.

NEW YORK (GenomeWeb) – Foundation Medicine has filed a lawsuit against Guardant Health, alleging that the company willfully infringes one of its recently awarded patents.

In the complaint, filed yesterday with the US District Court for the Eastern District of Texas, Marshall Division, Foundation Medicine claims that the Guardant360 cell-free tumor DNA liquid biopsy test infringes its US Patent No. 9,340,830.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.

Sep
27
Sponsored by
Philips Genomics

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Oct
12
Sponsored by
PierianDx

This webinar will be a roundtable discussion on the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers. 

Oct
17
Sponsored by
Cofactor Genomics

This webinar will discuss the benefits of genomically profiling the immune microenvironment of soft tissue sarcomas during neoadjuvant therapy.